ArticleCureus2024
Comparative Efficacy and Safety of the β3-Adrenoceptor Agonist Vibegron for Urgency and Mixed Urinary Incontinence: A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To compare the efficacy of vibegron for urgency urinary incontinence (UUI) and mixed urinary incontinence (MUI) in patients with overactive bladder (OAB). Methods We performed a post hoc analysis of a phase 3 study of vibegron in Japanese patients with OAB. Based on the patterns recorded in the three-day bladder diary, only female patients were categorized into UUI and MUI populations. The primary endpoint was the change in the mean micturition number per 24 hours from baseline to week 12. Other endpoints included the mean changes in urgency episodes per 24 hours, incontinence episodes per 24 hours, voided volume per micturition, and the number of nocturia episodes per night. The proportion of urinary incontinence (UI) normalization, quality of life (QOL) as measured by the King's Health Questionnaire (KHQ), and patient satisfaction level as assessed by the Patient Global Impression (PGI) were investigated. Result Data from a UUI population (vibegron 50 mg, n = 237; vibegron 100 mg, n = 231; placebo, n = 237) and an MUI population (vibegron 50 mg, n = 70; vibegron 100 mg, n = 77; placebo, n = 78) were analyzed. Vibegron 50 mg and 100 mg significantly improved the change in micturition number per 24 hours from baseline to week 12. Compared to those of patients receiving a placebo, all other endpoints of urinary parameters were significantly improved in patients receiving vibegron, except for nocturia in the vibegron 50 mg group in both populations. In the vibegron 50 mg, vibegron 100 mg, and placebo groups, the proportions of those who attained normalization of UI were stratified by the UUI (51.5%, 57.6%, and 44.7%, respectively) and MUI (40.0%, 41.6%, and 20.5%, respectively) populations. Furthermore, both vibegron doses improved KHQ scores in both populations, and PGI improvement was significantly higher than that in the placebo group in both populations. Conclusion This post hoc analysis demonstrated that vibegron has equivalent efficacy and safety in the MUI and UUI populations. The results of this study provide important information for the treatment of MUI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.